InnumeSensor virus cell background

Our Company

ImmuneSensor Therapeutics is a clinical-stage biotechnology company led by a team of experienced biotech executives who are committed to creating novel treatments that harness the body’s innate immune system to treat a wide range of diseases. Leveraging the extensive versatility and therapeutic potential of the cGAS-STING pathway, we are focused on discovering and developing novel medicines that address inflammatory and autoimmune diseases, along with cancers. Our growing pipeline includes cGAS inhibitors, which work to suppress inflammation and autoimmunity as well as STING agonists, designed to elicit anticancer immunity.

Pioneers of cGAS/cGAMP

Our History

ImmuneSensor was founded in 2014 based on the seminal research conducted by Dr. Zhijian James Chen's laboratory at the University of Texas Southwestern Medical Center. In 2012, his groundbreaking discovery of the cyclic GMP-AMP synthase (cGAS) enzyme and the secondary messenger, cyclic GMP-AMP (cGAMP), quickly spawned the scientific community's interest and subsequent research into the role of the cGAS-STING pathway in innate immunity. The importance of the pathway in activating the immune system and its broad applicability in many diseases is now widely recognized and has catalyzed intense drug development in Biopharma.

Since our Company's founding in 2014 and in-licensing intellectual property from UTSW, our team has built a promising pipeline of cGAS inhibitors and STING agonists with first- and best-in-class potential.

Company Milestones

Our Facility

Our headquarters and lab facilities are based in Dallas, Texas, a short distance from the world-renowned UTSW medical center. ImmuneSensor’s team of passionate and highly talented scientists and biotech professionals is proud to collaborate alongside global researchers and investigators, clinical trial facilities, corporate partners and contract research organizations.